Abstract
Age-related macular degeneration (AMD) remains a disease with high morbidity and an incompletely understood pathophysiological mechanism. The ocular blood supply has been implicated in the development of the disease process, of which most research has focused on the role of the choroid and choriocapillaris. Recently, interest has developed into the role of the retinal vasculature in AMD, particularly with the advent of optical coherence tomography angiography (OCTA), which enables non-invasive imaging of the eye's blood vessels. This review summarises the up-to-date body of work in this field including the proposed links between observed changes in the retinal vessels and the development of AMD and potential future directions for research in this area. The review highlights that the strongest evidence supports the observation that patients with early to intermediate AMD have reduced vessel density in the superficial vascular complex of the retina, but also emphasises the need for caution when interpreting such studies due to their variable methodologies and nomenclature.
Introduction
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss globally. While research has traditionally focused on the choroid—the primary vascular supply beneath the retina—and the accumulation of drusen, the retina's own internal blood supply is increasingly recognized as a critical factor. The retinal vasculature consists of multiple capillary networks that support the high metabolic demands of the inner retinal layers. Understanding how these vessels change during AMD progression could provide new insights into the disease's pathogenesis and offer novel biomarkers for early detection.
Mapping the Retinal Vasculature with OCTA
Historically, imaging the fine capillary beds of the retina was limited by the invasive nature of dye-based angiography. The emergence of Optical Coherence Tomography Angiography (OCTA) has revolutionized this field by providing non-invasive, three-dimensional visualization of retinal blood flow. OCTA allows for the quantification of metrics such as Vessel Density (VD) and the characterization of the Foveal Avascular Zone (FAZ).
A significant challenge in current research is the lack of standardized nomenclature. Different OCTA platforms and studies utilize varying segmentation strategies to define the retinal vascular layers. As shown in Figure 3, the proposed nomenclature aims to unify these layers into the Superficial Vascular Complex (SVC) and the Deep Vascular Complex (DVC), mapping them more accurately to their corresponding anatomical layers.
Key Findings and Clinical Insights
The synthesis of over 20 clinical studies reveals several consistent trends:
- Superficial Vascular Complex (SVC) Compromise: The most robust finding across the literature is a significant reduction in vessel density within the SVC in patients with early-to-intermediate AMD. This layer primarily supplies the ganglion cell layer (GCL).
- Structure-Function Correlation: Reductions in SVC vessel density often correlate with thinning of the GCL, raising questions about whether vascular dropout is a primary event or secondary to neuronal loss.
- Spatial Distribution: Vascular changes are not uniform; drop-out is frequently more pronounced in the temporal macula and the parafoveal region.
- Deep Vascular Complex (DVC) Variability: Findings regarding the DVC are less consistent, likely due to technical limitations such as "shadowing" artifacts from the superficial vessels which can obscure deeper layers.
Discussion and Future Directions
While the evidence for retinal vascular involvement in AMD is growing, several hurdles remain. Most existing studies are cross-sectional, making it difficult to establish causality. It remains unclear if these vascular changes precede clinical signs of AMD or are a consequence of the disease process. Furthermore, the lack of standardization across different OCTA devices—which use varying algorithms for vessel density calculation—complicates the comparison of results across different cohorts.
Future research must prioritize longitudinal studies to track vascular changes over time. Additionally, the adoption of standardized nomenclature and the development of automated, machine-learning-based analysis tools will be essential to translate these findings into reliable clinical biomarkers for AMD management.
Summary updated